Iconovo (ICO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iconovo (ICO) has a cash flow conversion efficiency ratio of -0.067x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.93 Million ≈ $-853.07K USD) by net assets (Skr117.92 Million ≈ $12.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Iconovo - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Iconovo's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Iconovo debt and liabilities for a breakdown of total debt and financial obligations.
Iconovo Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iconovo ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
COINSILIUM GROUP LTD
F:5CT
|
N/A |
|
Commerce Split Corp
TO:YCM
|
N/A |
|
Sonoro Energy Ltd
V:SNV
|
0.543x |
|
Canadian Premium Sand Inc
V:CPS
|
0.192x |
|
M3-Brigade Acquisition V Corp. Warrant
NASDAQ:MBAVW
|
N/A |
|
FD Technologies Plc
LSE:FDP
|
0.086x |
|
Tapaco Public Company Limited
BK:TAPAC
|
0.056x |
|
Cambridge Technology Enterprises Limited
NSE:CTE
|
0.319x |
Annual Cash Flow Conversion Efficiency for Iconovo (2016–2025)
The table below shows the annual cash flow conversion efficiency of Iconovo from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see ICO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr117.92 Million ≈ $12.69 Million |
Skr-31.87 Million ≈ $-3.43 Million |
-0.270x | -42.31% |
| 2024-12-31 | Skr129.21 Million ≈ $13.91 Million |
Skr-24.54 Million ≈ $-2.64 Million |
-0.190x | +44.15% |
| 2023-12-31 | Skr113.53 Million ≈ $12.22 Million |
Skr-38.60 Million ≈ $-4.15 Million |
-0.340x | +30.53% |
| 2022-12-31 | Skr89.29 Million ≈ $9.61 Million |
Skr-43.70 Million ≈ $-4.70 Million |
-0.489x | -509.02% |
| 2021-12-31 | Skr137.03 Million ≈ $14.75 Million |
Skr-11.01 Million ≈ $-1.19 Million |
-0.080x | +53.31% |
| 2020-12-31 | Skr92.73 Million ≈ $9.98 Million |
Skr-15.96 Million ≈ $-1.72 Million |
-0.172x | -54.97% |
| 2019-12-31 | Skr108.79 Million ≈ $11.71 Million |
Skr-12.08 Million ≈ $-1.30 Million |
-0.111x | -599.12% |
| 2018-12-31 | Skr63.99 Million ≈ $6.89 Million |
Skr-1.02 Million ≈ $-109.38K |
-0.016x | +86.88% |
| 2017-12-31 | Skr31.52 Million ≈ $3.39 Million |
Skr-3.82 Million ≈ $-410.77K |
-0.121x | -117.56% |
| 2016-12-31 | Skr8.73 Million ≈ $939.49K |
Skr6.02 Million ≈ $647.74K |
0.689x | -- |
About Iconovo
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more